Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma

Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma

Despite the success of standard front-line chemotherapy, 20% of classical Hodgkin lymphoma (cHL) patients still relapse or have refractory disease (r/r), and a subset of them die due to disease progression. There is a critical lack of predictive factors for early identification of those r/r patients...

Full description

Bibliographic Details
Main Authors: Claire Lamaison, Juliette Ferrant, Pauline Gravelle, Alexandra Traverse-Glehen, Hervé Ghesquières, Marie Tosolini, Cédric Rossi, Loic Ysebaert, Pierre Brousset, Camille Laurent, Charlotte Syrykh
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
Hodgkin lymphoma
immune prognosis signature
histological subtypes
gene expression profiling
Online Access:https://www.mdpi.com/2072-6694/14/19/4893

Similar Items

Similar Items